Verge Genomics Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 56

Employees
  • Latest Deal Type
  • Series B1

  • Latest Deal Amount
  • $98M

  • Investors
  • 31

Verge Genomics General Information

Description

Developer of a drug discovery platform designed to accelerate the development of life-saving treatments for neurodegenerative diseases. The company's platform utilizes machine learning to develop therapeutics, specifically for neurological diseases and can analyze datasets of any size, to identify new targets and predict effective drugs, enabling healthcare providers to improve patient outcomes as well as fundamentally bend the cost curve of pharmaceutical development.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Technology Systems
Biotechnology
Primary Office
  • Two Tower Place
  • Suite 950
  • San Francisco, CA 94080
  • United States

Verge Genomics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Verge Genomics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B1) 15-Dec-2021 $98M 00000 00000 Completed Pre-Clinical Trials
6. Later Stage VC (Series B) 01-Nov-2021 000.00 Completed Pre-Clinical Trials
5. Later Stage VC (Series A) 30-Jun-2020 000.00 Completed Pre-Clinical Trials
4. Early Stage VC (Series A1) 25-Jan-2019 000.00 000.00 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 16-Jul-2018 0000 000.00 0000 Completed Pre-Clinical Trials
2. Seed Round 28-Oct-2015 $4M $4.12M Completed Startup
1. Accelerator/Incubator 18-Aug-2015 $120K $120K 00.000 Completed Startup
To view Verge Genomics’s complete valuation and funding history, request access »

Verge Genomics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A6 000,000 00.000000 00 00.00 00.00 00 00.00 0.00
Series A5 000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series A4 00,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A3 0,000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series A2 1,698,104 $0.000100 6% $2.65 $2.65 1x $2.65 3.69%
Series A1 13,622,216 $0.000100 6% $3.31 $3.31 1x $3.31 29.62%
To view Verge Genomics’s complete cap table history, request access »

Verge Genomics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a drug discovery platform designed to accelerate the development of life-saving treatments for neurodegener
Drug Discovery
San Francisco, CA
56 As of 2022
00000
0000 0000-00-00
00000000000 00000

00000

irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Except
0000 000000000
Salt Lake City, UT
00 As of 0000
00000
000000000 00000

00 000

por incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
0000 000000000
Guilford, CT
00 As of 0000
0000
000000000 - 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Verge Genomics Competitors (50)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Clene Nanomedicine Formerly VC-backed Salt Lake City, UT 00 00000 000000000 00000
00 000000000000 Venture Capital-Backed Guilford, CT 00 0000 000000000 - 0000
0000000 Venture Capital-Backed Singapore, Singapore 00 00000 00000000000 00000
000000 Venture Capital-Backed Seattle, WA 00 000.00 00000000000 000.00
0000000 Venture Capital-Backed Framingham, MA 00 000.00 00000000000 000.00
You’re viewing 5 of 50 competitors. Get the full list »

Verge Genomics Patents

Verge Genomics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021207804-A1 Substituted pyrazolo-pyrimidines and uses thereof Pending 13-Jan-2020 0000000000
CA-3167339-A1 Substituted pyrazolo-pyrimidines and uses thereof Pending 13-Jan-2020 0000000000
EP-4090426-A1 Substituted pyrazolo-pyrimidines and uses thereof Pending 13-Jan-2020 0000000000
EP-4069699-A1 Fused tricyclic heterocyclic compounds as inhibitors of pikfyve kinase useful for the treatment of neurological diseases Pending 05-Dec-2019 00000000000
US-20170360805-A1 Motor-associated neurodegenerative disease and methods of treatment Inactive 16-Jun-2016 A61K31/573
To view Verge Genomics’s complete patent history, request access »

Verge Genomics Executive Team (10)

Name Title Board Seat Contact Info
Alice Zhang Ph.D Co-Founder, Chief Executive Officer & Board Member
John Applegate Chief Financial Officer
Robert Scannevin Ph.D Chief Scientific Officer
Michelle Mighdoll Director, Business Development & Corporate Strategy
Jason Chen MD Co-Founder & Advisor
You’re viewing 5 of 10 executive team members. Get the full list »

Verge Genomics Board Members (9)

Name Representing Role Since
Alfred Sandrock Jr. Self Board Member 000 0000
Alice Zhang Ph.D Verge Genomics Co-Founder, Chief Executive Officer & Board Member 000 0000
Andrew Allen Ph.D Self Board Member 000 0000
Dave Madge WuXi AppTec Board Observer 000 0000
Emily Melton Self Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Verge Genomics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Verge Genomics Investors (31)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BlackRock Asset Manager Minority 000 0000 000000 0
Cercano Management Venture Capital Minority 000 0000 000000 0
Eli Lilly Corporation Minority 000 0000 000000 0
Merck Global Health Innovation Fund Corporate Venture Capital Minority 000 0000 000000 0
Section 32 Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 31 investors. Get the full list »